11C-Choline PET/CT in the diagnosis of primary prostate cancer. Impact on treatment planning

Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial Staging

“…In a recent study by López et al, radiation treatment plan was changed on the basis of 11 C-choline PET/CT findings in 37.5% of the patients, resulting in good clinical and biochemical control and fewer or no side effects or less toxicity (47). Garcia et al showed the feasibility of dose escalation for nodal metastases in 11 of 61 patients with biopsy-proven intermediate-or high-risk PC on the basis of 11 C-choline PET/CT findings (48). Further trials are necessary to define the role of 11 C-or 18 F-choline PET/CT in radiation treatment planning.…”

Radiopharmaceuticals as probes to characterize tumour tissue

“…Additionally, 18 F-fluorocholine PET has shown utility for detection of bone metastasis, particularly in the early phase of bone metastasis [38,188], although uptake in bone can be influenced by hormone therapy. Numerous clinical studies were published in 2014, indicating the utility of choline tracers in patient management and treatment planning in prostate cancer [26][27][28]32].…”

Advances in imaging modalities in prostate cancer

“…The pooled detection rate increased to 65% when PSA doubling time was 6 months or less and to 71 and 77% when PSA velocity was higher than 1 or higher than 2 ng/ml/year, respectively. During the last year, several studies have been published with choline PET/CT describing optimization of technique [33][34][35][36][37][38][39][40], and staging [41][42][43][44][45], restaging [46][47][48][49][50][51][52][53][54], radiation treatment planning [55 & ,56], and evaluation of treatment response [57]. Furthermore, two studies reported a prognostic value of choline PET/CT [58,59 & ].…”